IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ImmunityBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$8.42−0.76 (-8.28%)
Close on Oct 19, 2026
- Market cap
- $8.84B
- P/E (TTM)
- –
- Dividend yield
- –
ImmunityBio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Market Cap | $8.92B | $197.05M |
| Enterprise Value | $8.57B | $106.56M |
| PS Ratio | 53.83 | 3.93 |
Enterprise value
| Measure | ImmunityBio | Industry median |
|---|---|---|
| EV / Sales | 51.68 | 2.69 |
Income (trailing twelve months)
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Revenue | $165.79M | $57.94M |
| Gross Profit | $164.70M | $90.47M |
| Operating Income | -$251.80M | -$21.44M |
| Pretax Income | -$992.58M | -$14.45M |
| Net Income | -$992.36M | -$22.46M |
| EBITDA | -$235.20M | -$16.91M |
| EPS (Diluted) | -$0.97 | -$0.83 |
Margins
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Gross Margin | 99.3% | 52.3% |
| Operating Margin | -151.9% | -44.5% |
| Pretax Margin | -598.7% | -13.0% |
| Profit Margin | -598.6% | -39.2% |
| EBITDA Margin | -141.9% | -31.3% |
| FCF Margin | -173.8% | -8.85% |
Returns
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Return on Assets (ROA) | -192.6% | -41.0% |
| Return on Capital Employed (ROCE) | -45.6% | -37.8% |
Growth
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 192.9% | 6.01% |
| Revenue Growth (3Y CAGR) | 678.6% | 2.25% |
| Revenue Growth (5Y CAGR) | 184.8% | 6.42% |
Balance sheet
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $357.37M | $62.42M |
| Net Cash (Debt) | $357.37M | $15.68M |
| Net Cash Per Share | $0.34 | $0.65 |
| Equity (Book Value) | -$1.05B | $48.79M |
| Book Value Per Share | -$0.99 | $1.36 |
| Tangible Book Value | -$1.05B | $23.06M |
| Working Capital | $362.25M | $75.77M |
Financial position
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Current Ratio | 5.72 | 3.30 |
| Quick Ratio | 5.35 | 2.39 |
Cash flow (trailing twelve months)
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Operating Cash Flow | -$281.14M | -$12.35M |
| Capital Expenditures | -$6.94M | -$1.06M |
| Free Cash Flow | -$288.07M | -$20.28M |
| FCF Per Share | -$0.27 | -$0.41 |
Efficiency
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Asset Turnover | 0.32 | 0.38 |
| Inventory Turnover | 0.26 | 2.67 |
| Revenue Per Employee | $239.93K | $398.96K |
| Profits Per Employee | -$1.44M | -$732.08K |
| Employee Count | 691 | 73 |
Dividends and yields
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Earnings Yield | -11.1% | -21.2% |
| FCF Yield | -3.23% | -7.64% |
Shares
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Shares Outstanding | 1,059,840,000 | 59,128,900 |
| Shares Change (YoY) | 26.5% | 11.1% |
| Shares Change (QoQ) | 0.56% | 0.54% |
| Float | 262,247,000 | 48,744,500 |
| Shares Held by Insiders | 75.3% | 11.8% |
| Shares Held by Institutions | 19.1% | 59.4% |
Taxes
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Income Tax | -$161.00K | $91.50K |
Scores
| Measure | ImmunityBio | Industry median |
|---|---|---|
| Altman Z-Score | -7.39 | 0.10 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from ImmunityBio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.